Compare BBIO & DT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBIO | DT |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 15.2B |
| IPO Year | 2019 | 2019 |
| Metric | BBIO | DT |
|---|---|---|
| Price | $65.88 | $35.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 23 |
| Target Price | ★ $79.91 | $53.57 |
| AVG Volume (30 Days) | 2.8M | ★ 6.3M |
| Earning Date | 05-22-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 205.77 |
| EPS | N/A | ★ 0.48 |
| Revenue | $502,076,000.00 | ★ $1,698,683,000.00 |
| Revenue This Year | $85.55 | $21.68 |
| Revenue Next Year | $71.10 | $14.85 |
| P/E Ratio | ★ N/A | $71.35 |
| Revenue Growth | ★ 126.26 | 18.75 |
| 52 Week Low | $28.33 | $33.24 |
| 52 Week High | $84.94 | $59.92 |
| Indicator | BBIO | DT |
|---|---|---|
| Relative Strength Index (RSI) | 36.59 | 37.38 |
| Support Level | $61.54 | $33.24 |
| Resistance Level | $68.71 | $50.99 |
| Average True Range (ATR) | 4.46 | 1.57 |
| MACD | -0.77 | 0.03 |
| Stochastic Oscillator | 17.00 | 26.13 |
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Dynatrace is a software-as-a-service company that enables customers to monitor and analyze their information technology infrastructure, from servers to applications and Python scripts. Dynatrace's unified platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to optimize their business for service-level objectives and ensure uptime.